Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

Healthcare Medical Devices
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

NetraMark Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(127)
•••
Post by SkywalkerofLukeon Mar 08, 2022 5:05pm
184 Views
Post# 34497208

News

News

$MEND.c $MNNDF in the green today as they announced their CSO and Director Of Bioinformatics received the 'Highly Cited Paper' award from the peer-reviewed journal, Exploration of Medicine.


The research further validates $MEND ‘s AI platform and provides novel insights into Alzheimer's disease that has a diagnostics and therapeutics market valued at USD $7B.


Great to see $MEND getting recognized for their work, hopefully it starts reflecting in their sp.


https://www.newswire.ca/news-releases/nurosene-s-cso-and-director-of-bioinformatics-receives-highly-cited-paper-award-for-ai-based-alzheimer-s-research-findings-820276049.html

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities